
													
															
															Year
															DEALS // DEV.
															Country
															
															Therapeutic Area
															Study Phase
															Deal Type
															Product Type
															Dosage Form
															Lead Product
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SRT-015
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Genfit
Deal Size : $106.8 million
Deal Type : Licensing Agreement
GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset
Details : Under the agreement, GENFIT has gained the exclusive worldwide rights of SRT-015, a highly optimized, first-in-class ASK1 inhibitor being developed in acute-on-chronic liver failure (ACLF), from Seal Rock Therapeutics.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 31, 2023
Lead Product(s) : SRT-015
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Genfit
Deal Size : $106.8 million
Deal Type : Licensing Agreement

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SRT-015
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SRT-015 is a second generation apoptosis signal-regulating kinase (ASK1) inhibitor for treatment of alcoholic hepatitis, non-alcoholic steatohepatitis (NASH) and other liver diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 24, 2022
Lead Product(s) : SRT-015
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SRT-015
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The presentations demonstrate superior pharmacological properties of SRT-015 compared to other ASK1 inhibitors, including selonsertib, and provide potential explanations for the failure of selonsertib in clinical trials.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 16, 2020
Lead Product(s) : SRT-015
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SRT-015
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Seal Rock Therapeutics Announces Upcoming Presentations at AASLD's The Liver Meeting® 2020
Details : Posters to highlight excellent efficacy of SRT-015 in NASH-relevant models, and comparator data with the ASK1 inhibitor selonsertib that is consistent with its lack of efficacy in phase 3 trials.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 02, 2020
Lead Product(s) : SRT-015
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
